A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
about
A phase I study of volasertib combined with afatinib, in advanced solid tumors.A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors.Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on AfatinibA highly efficient and sensitive LC-MS/MS method for the determination of afatinib in human plasma: application to a metabolic stability study.Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumorsClinical Pharmacokinetics and Pharmacodynamics of Afatinib.Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.Afatinib: first global approval.Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.Afatinib for the treatment of advanced non-small-cell lung cancer.Afatinib in the treatment of breast cancer.Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.Afatinib and lung cancer.Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.Afatinib in squamous cell carcinoma of the head and neck.A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.
P2860
Q33425698-E3399531-E7F9-43BB-8F4F-2A390A2CD57CQ33556988-49B49C88-D68E-46CC-A4B7-E5CD30F76148Q35788884-3E5F21A1-5B89-466D-BB78-374C818F9727Q35807946-360CCE66-5BB9-4480-8A04-7E2D8D1C3132Q35873072-0810157D-9D9D-4663-BEFF-7D16A7F18222Q36750974-E370E2D4-0F61-4816-B3CF-5C094AD9E09EQ36816522-01302EA0-C389-4809-852D-E0E0BBFED58EQ37650711-D1E02408-B4D3-4F87-B97C-9F8D04D347B5Q37735587-348AD1A8-CFE7-4063-8770-FEAB1B2E09E7Q38132049-D722FBAF-A0ED-4366-94BF-22FB210AE9F0Q38179266-C88852A6-85AE-4EF4-9562-8664E1629EDDQ38197278-4645B548-4306-4A9D-A96A-AE65408A15B2Q38215591-DD3218EE-F2AE-4841-9A8C-9EB85786B643Q38262804-487BBDB8-6E1F-455D-B544-844A24514F00Q38270627-891FADE4-1055-4EAE-8C3B-79B23C74A18FQ38575289-42578D25-D715-4D41-8812-4631F2637068Q38728508-7FA01C98-D768-47B5-8E28-B0510589EDADQ38829891-69FF9662-B9B2-4605-80A9-E66405F038EEQ39008385-7383540F-A837-49DD-B2C0-E3FA0ADA8304Q39297048-1B7E8BC0-CFE5-415F-8FA4-C0D2DE01B030Q45662172-86A106E9-DD57-4D41-B6D4-07332307EDD4
P2860
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
A Phase I, open-label, dose es ...... ts with advanced solid tumors.
@ast
A Phase I, open-label, dose es ...... ts with advanced solid tumors.
@en
type
label
A Phase I, open-label, dose es ...... ts with advanced solid tumors.
@ast
A Phase I, open-label, dose es ...... ts with advanced solid tumors.
@en
prefLabel
A Phase I, open-label, dose es ...... ts with advanced solid tumors.
@ast
A Phase I, open-label, dose es ...... ts with advanced solid tumors.
@en
P2093
P2860
P1476
A Phase I, open-label, dose es ...... ts with advanced solid tumors.
@en
P2093
Ferry A L M Eskens
Herman Burger
Jimmy Hwang
John Marshall
Mahmoud Ould-Kaci
Martina Uttenreuther-Fischer
Nancy L Lewis
Peter Stopfer
Roger B Cohen
Shakun Malik
P2860
P2888
P304
P356
10.1007/S10637-012-9890-Y
P577
2012-11-17T00:00:00Z